Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: Involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity

Journal of Neurochemistry

Volumn 89, Issue 6, 2004, Pages 1479-1489

  Popoli, Patrizia ^a   Pintor, Annita ^a   Tebano, Maria Teresa ^a   Frank, Claudio ^a   Pepponi, Rita ^a   Nazzicone, Valeria ^a   Grieco, Rosa ^a   Pèzzola, Antonella ^a   Reggio, Rosaria ^a   Minghetti, Luisa ^a   De Berardinis, Maria Anna ^a   Martire, Alberto ^a   Potenza, Rosa Luisa ^a   Domenici, Maria Rosaria ^a   Massotti, Marino ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Excitotoxicity; Huntington disease; Metabotropic glutamate receptor 5; Neuroprotection; Striatum

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; CALCIUM; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOLINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CALCIUM CELL LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ADMINISTRATION ROUTE; DRUG MECHANISM; ELECTROENCEPHALOGRAM; ENZYME RELEASE; FEMALE; INTRASTRIATAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; CALCIUM; CELLS, CULTURED; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; L-LACTATE DEHYDROGENASE; MALE; MAZE LEARNING; MICRODIALYSIS; N-METHYLASPARTATE; NEOSTRIATUM; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NEUROTOXINS; PYRIDINES; QUINOLINIC ACID; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE;

ANIMALIA;

EID: 3042522901     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02448.x     Document Type: Article

References (52)

1. Alexi T., Borlongan C. V., Faull R. L. M., Williams C., Clark R. G., Gluckman P. D. and Hughes P. E. (2000) Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's disease. Prog. Neurobiol. 60, 409-470.
2. Allen J. W., Knoblach S. M. and Faden A. I. (2000) Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro. Cell. Death Differ 7, 470-476.
3. Awad H., Hubert G. W., Smith Y., Levey A. I. and Conn P. J. (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 20, 7871-7879.
4. Bao W. L., Williams A. J., Faden A. I. and Tortella F. C. (2001) Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res. 922, 173-179.
5. Battaglia G., Bruno V., Pisani A., Centonze D., Catania M. V., Calabresi P. and Nicoletti F. (2001) Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission. Mol. Cell. Neurosci. 17, 1071-1083.
6. Battaglia G., Fornai F., Busceti C. L., Aloisi G., Cerrito F., De Blasi A., Melchiorri D. and Nicoletti F. (2002) Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J. Neurosci. 22, 2135-2141.
7. Beal M. F., Brouillet E., Jenkins B. G., Ferrante R. J., Kowall N. W., Miller J. M., Strorey E., Srivastava R., Rosen B. R. and Hyman B. T. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mithocondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192.
8. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swart Z. K. J. and Martin J. B. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171.
9. Biber K., Laurie D. J., Berthele A., Sommer B., Tolle T. R., Gebicke-Harter P. J., van Calker D. and Boddeke H. W. (1999) Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem. 72, 1671-1680.
10. Blum D., Galas M. C., Gall D., Cuvelier L. and Schiffmann S. N. (2002) Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's diseases. Neurobiol. Dis. 10, 410-426.
11. Brewer G. J. (1997) Isolation and culture of adult rat hippocampal neurons. J. Neurosci. Meth 71, 145-158.
12. Bruno V., Battaglia G., Copani A., D'Onofrio M., Di Iorio P., De Blasi A., Melchiorri D., Flor P. J. and Nicoletti F. (2001) Metabotropic glutamate receptors as targets for neuroprotective drugs. J. Cerebr. Blood Flow Metab. 21, 1013-1033.
13. Bruno V., Battaglia G., Kingston A., O'Neill M. J., Catania M. V., Di Grezia R. and Nicoletti F. (1999) Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology 38, 199-207.
14. Bruno V., Ksiazek I., Battaglia G., Lukic S., Leonhardt T., Sauer D., Gasparini F., Kuhn R., Nicoletti F. and Flor P. J. (2000) Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39, 2223-2230.
15. Calabresi P., Maj R., Pisani A., Mercuri N. B. and Bernardi G. (1992) Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J. Neurosci. 12, 4224-4233.
16. Cha J.-H. J., Talati A., Kerner J. A., Lichtenbaum R. A. and Young A. B. (1996) Antisense oligodeoxynucleotides directed against mGluR5 glutamate receptors protect against malonic acid lesions in rat striatum. Neuropharmacology 35, A7.
17. Chen Q., Surmeier D. J. and Reiner A. (1999) NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization. Exp. Neurol. 159, 283-296.
18. Choi D. W. (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1, 623-634.
19. Choi D. W. (1992) Excitotoxic cell death. J. Neurobiol. 23, 1261-1276.
20. Connick J. H. and Stone T. W. (1988) Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br. J. Pharmacol. 93, 868-876.
21. Copani A., Casabona G., Bruno V., Caruso A., Condorelli D. F., Messina A., Di Giorgi Gerevini V., Pin J.-P., Kuhn R., Knopfel T. and Nicoletti F. (1998) The metabotropic glutamate receptor mGlu5 controls the onset of developmental apoptosis in cultured cerebellar neurons. Eur. J. Neurosci. 10, 2173-2184.
22. Doble A. (1999) The role of excitotoxicity in neurodegenerative diseases: implications for therapy. Pharmacol. Ther. 81, 163-221.
23. Domenici M. R., Pintor A., Potenza R. L., Gaudi S., Grò M. C., Passarelli F., Reggio R., Galluzzo M., Massotti M. and Popoli P. (2003) Metabotropic glutamate receptor 5 (mGluR5)-mediated phosphoinositide hydrolysis and NMDA-potentiating effects are blunted in the striatum of aged rats: a possible additional mechanism in striatal senescence. Eur. J. Neurosci. 17, 2047-2055.
24. Faden A. I., O'Leary D. M., Fan L., Bao W., Mullins P. G. and Movsesyan V. A. (2001) Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improves outcome after brain trauma. Exp. Neurol. 167, 435-444.
25. 10 and remacemide in transgenic mouse models of Huntington's diseases. J. Neurosci. 22, 1592-1599.
26. Flor P. J., Battaglia G., Nicoletti F., Gasparini F. and Bruno V. (2002) Neuroprotective activity of metabotropic glutamate receptor ligands. Adv. Exp. Med. Biol. 513, 197-223.
27. Gasparini F., Lingenhöl K., Stoehr N., Flor P. J., Heinrich M., Vranesic I., Biolla Z. M., Allgeier H., Heckendom R., Urwyler S., Vamey Varney M. A., Johnson E. C., Hess S. D., Rao S. R., Sacaan A. I., Santori E. M., Veliçelebi G. and Kuhn R. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38, 1493-1503.
28. Greco A., Minghetti L. and Levi G. (2000) Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem. Res. 25, 1357-1364.
29. Lee J. M., Zipfel G. J. and Choi D. W. (1999) The changing landscape of ischemic brain injury mechanisms. Nature 399, A7-A14.
30. Menalled L. B. and Chesselet M.-F. (2002) Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23, 32-39.
31. Minghetti L., Greco A., Cardone F., Puopolo M., Ladogana A., Almonti S., Cunningham C., Perry V. H., Pocchiari M. and Levi G. (2000) Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human experimental transmissible spongiform encephalopathies. J. Neuropathol. Exp. Neurol. 59, 866-871.
32. Montine T. J., Beal M. F., Robertson D., Cudkowic Z. M. E., Biaggioni I., O'Donnel H., Zackert W. E., Roberts L. J. and Morrow J. D. (1999) Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology 52, 1104-1105.
33. Moroni F., Attucci S., Cozzi A., Meli E., Picca R., Scheideler M. A., Pellicciari R., Noe C., Sarichelou I. and Pellegrini-Giampietro D. E. (2002) The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death. Neuropharmacology 42, 741-751.
34. Morrow J. D. and Roberts L. J. (1997) The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36, 1-21.
35. Movsesyan V. A., O'Leary D. M., Fan L., Bao W., Mullins P. G. M., Knoblach S. M. and Faden A. I. (2001) mGluR5 antagonists 2-Methyl-6- (phenylethynyl)-pyridine and (E)-2-Methyl-6 - (phenylethynyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-Methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 296, 41-47.
36. Nicoletti F., Bruno V., Catania M. V., Battaglia G., Copani A., Barbagallo G., Ceña V., Sanchez-Prieto J., Spano P. F. and Pizzi M. (1999) Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology 38, 1477-1484.
37. Nicoletti F., Bruno V., Copani A., Casabona G. and Knöpfel T. (1996) metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 1, 267-271.
38. O'Leary D. M., Movsesyan V., Vicini S. and Faden A. I. (2000) Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 131, 1429-1437.
39. Orlando L. R., Alsdorf S. A., Penney J. B. Jr and Young A. B. (2001) The role of Group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp. Neurol. 167, 196-204.
40. Pellegrini-Giampietro D. E., Peruginelli F., Meli E., Cozzi A., Albani-Torregrossa S., Pellicciari R. and Moroni F. (1999) Protection with metabotropic glutamate receptor 1 antagonists in models of ischemic neuronal death: time-course and mechanisms. Neuropharmacology 38, 1607-1619.
41. 2A receptors. Neuroreport 11, 3611-3614.
42. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., Bernardi G. and Calabresi P. (2001) Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106, 579-587.
43. 2A receptors reduces, through a pre-synaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22, 1967-1975.
44. 2 receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res. 831, 315-318.
45. Santamaria A., Jiménez-Capdeville M. E., Camacho A., Rodriguez-Martine Z. E., Flores A. and Galvàn-Arzate S. (2001) In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport 12, 2693-2696.
46. Spooren W. P. J. M., Gasparini F., Salt T. E. and Kuhn R. (2001) Novel allosteric antagonists shed light on mGlu5 receptors and CNS disorders. Trends Pharmacol. Sci. 22, 331-337.
47. Stone T. W. (1993) Neuropharmacology of quinolinic and kinurenic acids. Pharmacol. Rev. 45, 309-379.
48. Stone T. W., Behan W. M. H., Jones P. A., Darlington L. G. and Smith R. A. (2001) The role of kynurenines in the production of neuronal death, and the neuroprotective effect of purines. J. Alzh. Dis. 3, 355-366.
49. Tallaksen-Greene S. J., Kaat Z. K. W., Romano C. and Albin R. L. (1998) Localization of mGluR1α-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Res. 780, 210-217.
50. Testa C. M., Standaert D. G., Landwehrmeyer G. B., Penney J. B. and Young A. B. (1995) Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurones. J. Comp. Neurol. 354, 241-252.
51. Thomas L. S., Jane D. E., Gasparini F. and Croucher M. J. (2001) Glutamate release inhibiting properties of the novel mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology 41, 523-527.
52. Ugolini A., Corsi M. and Bordi F, (1999) Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharmacology 38, 1569-1576.